Physician profile
John C Rollet
NPI 1932119112
$1,382.56
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $519 · 2021: $26.09 · 2022: $12.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $446.19 | 2019-2022 | |
| Pfizer INC. | $406.95 | 2019-2020 | |
| Astellas Pharma US INC | $102.60 | 2019 | |
| Amgen INC. | $94.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.64 | 2019 | |
| Allergan, INC. | $57.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $54.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.19 | 2019 | |
| Merck Sharp & Dohme LLC | $29.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2019 | |
| Nabriva Therapeutics, Plc | $17.48 | 2020 | |
| Genentech USA, INC. | $14.13 | 2019 | |
| Eisai INC. | $13.10 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.88 | 2019 | |
| Lilly USA, LLC | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rollet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.